The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel D...

Full description

Bibliographic Details
Main Authors: David M Lucas, Lapo Alinari, Derek A West, Melanie E Davis, Ryan B Edwards, Amy J Johnson, Kristie A Blum, Craig C Hofmeister, Michael A Freitas, Mark R Parthun, Dasheng Wang, Amy Lehman, Xiaoli Zhang, David Jarjoura, Samuel K Kulp, Carlo M Croce, Michael R Grever, Ching-Shih Chen, Robert A Baiocchi, John C Byrd
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-06-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2880605?pdf=render

Internet

http://europepmc.org/articles/PMC2880605?pdf=render

Similar Items